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Abstract
Background: Due to an increase in PTSD patients seeking help in the Danish mental health sector and the
addition of Complex PTSD to the ICD-11, there is a need to increase efficiency of existing treatments for PTSD.
mHealth interventions have been shown to reduce PTSD symptoms. Therefore, the implementation of a mHealth
intervention designed for psychiatric PTSD patients as a therapy add-on may improve treatment outcome. No study
to date has explored the effects of mHealth interventions for PTSD in the Danish mental health sector, the
feasibility and effect of this type of intervention needs testing.
Methods: The study is an investigator-initiated randomized controlled feasibility trial investigating the clinical
mHealth tool PTSD help combined with care as usual (CAU) compared to CAU for adults with PTSD. Seventy
patients will be recruited and receive either the mHealth intervention combined with CAU or CAU alone. The
primary feasibility outcome is the proportion of eligible patients that participate in the study until the end
assessment. Secondary outcome data consists of the fraction of compliant patients in the experimental group and
exploratory data on PTSD help on PTSD symptom severity, level of psychological distress, sleep quality, dissociation
symptoms, therapy readiness, quality of life, disability levels, and recovery.
Discussion: This study may help increase our knowledge of possible benefits of, as well as potential barriers to, the
implementation of mHealth tools in the psychiatric sector. It may also provide a cost-efficient means to increase
therapy outcomes and decrease the duration of suffering for PTSD patients in the psychiatric sector.
Trial registration: The trial is registered at ClinicalTrials.gov (ID: NCT03862703) https://clinicaltrials.gov/ct2/show/
NCT03862703 on the 27 of February 2019 and has been approved by the Danish Data Protection Agency (journal
number: VD-2018-200 ISuite number 6443). Referring to the committee law §2, the National Committee on Health
Research Ethics (DNVK) [H-18024180] decided that the study could proceed without approval as the use of PTSD
help did not constitute a health science intervention according to Danish health science legislation.
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Background
Post-traumatic stress disorder (PTSD) is a potentially
disabling and often protracted psychiatric disorder,
which may develop as a response to one or several se-
verely traumatic events. The prevalence of PTSD de-
pends on several factors (e.g., the diagnostic system and
assessment procedures), but across a range of European
countries, the lifetime prevalence of PTSD is estimated
to be approximately 2% [1]. The past years have seen a
marked increase in the number of patients referred for
PTSD treatment in Mental Health Services in the Cap-
ital Region of Denmark (MHS-CRD) from 453 in 2015
to 746 in 2017.
ICD-11 PTSD is comprised of three core symptoms: re-
experiencing, avoidance, and hyperarousal (World Health
Organization, 2018). In 2018, Complex PTSD (C-PTSD)
was included in ICD-11 (World Health Organization,
2018). It contains the core PTSD components and an add-
itional component reflecting “disturbances in self-
organization” (DSO) comprised of affective dysregulation,
negative self-concept, and disturbances in relationships [7,
18]. Furthermore, patients with C-PTSD are characterized
by a higher frequency of childhood traumatic experiences
and greater functional impairment [32] in comparison to
PTSD patients. Cloitre et al. [20] report that C-PTSD is a
predictor of drop-out and poor treatment response in
some of the current first-line treatments for PTSD, and it
has been suggested that this patient group may benefit
from stabilizing interventions prior to trauma-focused
psychotherapy [8, 17, 20]. Thus, there is a need to develop
new treatment approaches that include stabilizing inter-
ventions for patients with C-PTSD.
Over the last decade, psychiatric treatment providers
across the world have developed mobile technology both
as standalone treatments and as supplements to existing
treatments for mental health problems [5, 24]. The use
of mobile health tools (mHealth) in mental health care is
argued to have several potential advantages: mHealth
tools can be easily integrated in daily life [4], they can
reach people that do not normally seek mental health
treatment [46], they can assist patients in getting psychoe-
ducation [35, 40], and they can be used to monitor symp-
toms [14, 15, 35]. In addition, mHealth tools have the
potential to improve the cost-effectiveness of interventions
through the optimization of the clinicians’ time and re-
sources and improve treatment effect by improving ther-
apy engagement and adherence [14, 16, 21, 23, 48].
Existing clinical evaluations of mHealth tools have
found promising indications of their efficacy in reducing
patients’ symptoms and general level of psychological
distress [27, 38]. Clinical studies investigating mHealth
tools used as a psychotherapy add-on have also found
enhanced compliance with treatment [45, 47], and in-
creased treatment outcome, both immediately after end
of treatment, and at 6-month follow-up, which may be
partially due to an increase in patient adherence to
homework [10, 39]. However, more research is needed
to substantiate these results as most studies to date have
not been replicated or have had methodological limita-
tions such as a lack of control groups or small sample
sizes [23, 38, 39, 43].
So far, mHealth apps for PTSD patients have primarily
been designed for use by American veterans with PTSD
[34, 44]. To address the needs of non-veteran PTSD pa-
tients, we developed an mHealth app, PTSD help (Danish:
PTSD hjaelp), designed to supplement psychotherapeutic
treatment for PTSD across psychotherapeutic modalities
and PTSD subgroups. PTSD help focuses on psychoeduca-
tion (about PTSD symptoms, diagnosis, triggers, epidemi-
ology, treatment, prognosis, aetiology, and advice for next
of kin), emotion-regulating tools (e.g., breathing exercises,
grounding exercises, calming images, body exercises, sleep
advice, and guided meditations), crisis management (e.g.,
crisis plan), and finally, self-monitoring of PTSD symp-
toms and sleep quality. To ensure the usability of PTSD
help across treatment modalities, the app does not include
specific treatment elements as these are delivered in face-
to-face psychotherapeutic treatment.
We have found no studies of mHealth tools for PTSD
in a Danish treatment context, which makes it difficult
to ascertain possible roadblocks for the implementation
of mHealth tools in a Danish psychiatric context. How-
ever, a relatively broad implementation seems to be
practically possible, as more than 85% of all Danes be-
tween 15 and 75 years own a smartphone. Because PTSD
help is an untested clinical mHealth tool, it is necessary
to test if it is possible to successfully recruit patient for
an RCT testing efficacy of PTSD help, a Danish psychi-
atric context.
We therefore plan to conduct a feasibility study with the
primary aim of ascertaining feasibility of randomization
and investigate levels of patient compliance before con-
ducting a larger randomized controlled trial (RCT) on
treatment efficacy. The primary objective for the present
study is to assess the feasibility of using PTSD help in the
MHS-CRD to inform a larger future RCT study. The sec-
ondary objective is to gather preliminary exploratory data
on the effectiveness of PTSD help versus treatment as
usual on a range of clinically relevant outcome variables,
including exploring C-PTSD as a potential moderator of
subgroup-specific effects.
Methods
The study is an investigator-initiated randomized con-
trolled feasibility trial investigating PTSD help combined
with care as usual (CAU) compared to CAU for adults
with PTSD. The primary feasibility outcome is the pro-
portion of eligible patients that participates in the
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primary app intervention before entering psychotherapy
and provide data at the T1 (baseline) and T2 (post-app
intervention) assessment. The secondary feasibility out-
come is the fraction of compliant patients in the experi-
mental group, and additional explorative outcome data
consists of PTSD symptom severity, level of psychological
distress, sleep quality, dissociation symptoms, therapy
readiness, quality of life, negative events, and user satisfac-
tion. This data will be collected using electronic question-
naires administered via participants email.
The primary outcome will be assessed at T2 6 weeks
after randomization. The secondary feasibility outcome
will be assessed continuously by logging the patient’s in-
teractions with the application. Secondary outcomes will
be assessed prior to randomization and start of PTSD
help intervention (T1), at post-primary PTSD help inter-
vention (T2) and at the end of psychotherapeutic treat-
ment (T3). The design of this trial has been developed
with attention to the criteria outlined in the SPIRIT
2013 guidelines [13] (see Fig. 1 for a consort diagram).
Fig. 1 Consort diagram
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The trial is registered at ClinicalTrials.gov (ID:
NCT03862703) and has been reviewed by the Danish
Data Protection Agency (journal number: VD-2018-200
ISuite number 6443). Referring to the committee law §2,
the National Committee on Health Research Ethics
(DNVK) [H-18024180] decided that the study could
proceed without approval as the use of PTSD help did
not constitute a health science intervention according to
Danish health science legislation.
Participants
The study will recruit patients referred with PTSD
symptoms to the Centre for Visitation and Diagnostics
(CVD) under the MHS-CRD, with the following inclu-
sion criteria: the patient (1) must be at least 18 years old,
(2) fulfil the DSM-5 PTSD diagnosis criteria, (3) be re-
ferred to PTSD care package treatment [22], (4) have ac-
cess to a smartphone with iOS (Version 10 or higher) or
Android (Version 5.0.1 or higher), and (5) provide in-
formed consent. Exclusion criteria are patients with (1)
suicidal risk, (2) ongoing episode of bipolar disease or
psychotic disorder, (3) current abuse of alcohol or drugs,
(4) inability to understand and/or read Danish, and (5)
concurrent psychiatric or psychological treatment of
PTSD outside of MHS-CRD.
Randomization
Randomization is conducted through the data manage-
ment software REDCap, which allows a setup where no
one from the research team has knowledge of or access
to the underlying computer-generated allocation se-
quence. The randomization uses permuted blocks with
varying block sizes based on a computer-generated allo-
cation sequence created by a researcher with no affili-
ation to the project. The randomization allocation ratio
is 1:1. This procedure ensures that researchers are
blinded to the allocation process as the randomization
allocation list, and block size is unknown to the re-
searchers. The randomization procedure will be strati-
fied by presence of Complex PTSD as measured with
the International Trauma Questionnaire [18].
Blinding
Patients will be randomized after baseline assessment to
ensure assessors and patients are blinded during the as-
sessment. All assessments post-randomization will con-
sist solely of self-report measures administered via email
through REDCap and logging of user activity in the app.
Procedure
Patients referred to CVD for diagnostic screening that
are diagnosed with PTSD and accepted for PTSD out-
patient treatment in MHS-CRD will be invited to partici-
pate in the study by the clinician conducting the
screening. The invitation will include a leaflet with infor-
mation about the study and contact information for the
project. If the patient gives their consent for participation,
he or she will be booked for an assessment interview. Pa-
tients who provide written consent and complete the as-
sessment interview will be randomized if they fulfill the
inclusion/exclusion criteria. After randomization, patients
in the experimental group will be given immediate access
to PTSD help. After 3 days, they will receive a phone call
to ascertain whether they are experiencing any technical
difficulties using the app. The second and third as-
sessments will be administered electronically via a
link to the questionnaires sent in an email through
REDCap (see Fig. 1 for a consort diagram).
Interventions
PTSD treatment
All patients in the project will receive PTSD treatment at
one of six outpatient clinics in the MHS-CRD that pro-
vides PTSD treatment. All clinics comply with official Da-
nish recommendations for PTSD Care Packet-treatment
(CP-treatment) [22]. PTSD CP-treatment consists of 60 h
trauma-focused group psychotherapy or 15 h trauma-
focused individual therapy combined with other treatment
elements such as assessment, psychoeducation, pharmaco-
logical counselling/treatment, social skill training, meeting
with social network, and monitoring. The CP includes
75 h of treatment in total (Table 1).
PTSD help
The PTSD help app is designed for use in preparation
for and as a supplement to psychotherapy. The app in-
cludes a range of different functions. It contains psy-
choeducation about PTSD on a range of different topics
including PTSD symptoms, etiology, prognosis, treat-
ment, trauma in general, and information for next of kin
on how to offer support to individuals suffering from
PTSD. The app contains tools for self-assessment and
monitoring of PTSD symptoms (PTSD checklist for
DSM-5, [53]) and sleep quality (Sleep Condition Indica-
tor, [25]). For alleviating sleep problems, the app has two
Table 1 Care package treatment for post-traumatic stress
disorders
CP content hours
Psychiatric and somatic assessment 3 h
Psychometry (monitoring) and psychoeducation 2 h
Group psychotherapy 60 h
Psychopharmacology 2 h
Social skills training and couple counselling 4 h
Continuity and coherence in ongoing treatment 4 h
Total 75 h
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different audio-recorded guided meditations and advice
for improving sleep habits and sleep environment. It also
contains different tools and techniques for relieving anx-
iety such as distraction exercises, a breathing exercise
with an animated prompt to help the user regulate his
or her breath, physical relaxation and simple yoga exer-
cises, calming images accompanied with music, and an
option for taking personal notes on the experience of
specific symptoms and helpful strategies to reduce dis-
tress associated with these symptoms. And finally, it has
a crisis plan with personal contacts and contact informa-
tion for psychiatric emergency services. The features se-
lected for the app were chosen based on advice from
resident clinical experts and empirical evidence drawn
primarily from the cognitive behavioral tradition of psy-
choeducation and anxiety management training [28, 29]
and from cognitive behavioral treatment for insomnia
[11, 51]. In addition, some features based on yoga and
meditation practices were included, based on emerging
evidence for their potential effectiveness [30, 36]. PTSD
help was freely available to participants in the experi-
mental group, but is currently not broadly available for
download. The current build of the app will be kept
stable throughout the intervention.
Assessment interview
The patient’s trauma history is assessed with The Trauma
History Questionaire [31], a 24-item self-report measure
of the patient’s lifetime trauma history. PTSD diagnosis
and comorbid disorders are assessed through the Mini
International Neuropsychiatric Interview (MINI v. 7.02)
[50], a structured diagnostic interview that assesses the
presence of psychiatric disorders according to DSM-5. To
ascertain whether the patient also fulfills the criteria for
International Classification of diseases 11th revision pend-
ing (ICD-11) PTSD or C-PTSD, the International Trauma
Questionaire (ITQ) [19] is administered. ITQ is a 23-item
self-report questionnaire used to distinguish between
PTSD and C-PTSD as defined in ICD-11.
Feasibility outcome
The primary feasibility outcome is the proportion of eli-
gible patients that agree to be randomized and partici-
pate in assessment 1 (T1, week 1) and 2 (T2, week 7).
The secondary feasibility outcome is the fraction of
compliant patients in the experimental group that is pa-
tients that actively use the system after. Compliance is
defined as the use of PTSD help functions (excluding
self-monitoring tools) corresponding to use twice a week
(mean), assessed over 6 weeks pre-treatment, and during
the psychotherapy treatment period. Compliance data is
collected from the tracking log of the patient’s app activ-
ity through a secured webpage. In addition, compliance
will be assessed through a user behaviour questionnaire,
an 11-item questionnaire developed by the project group
for the current study by selecting and modifying relevant
items from questionnaires used in earlier studies evaluat-
ing the PTSD Coach app [34, 44] (see Additional file 1).
Exploratory outcomes
Exploratory outcomes in the study are app intervention
dropout rate, psychotherapy dropout rate, and a range of
patient outcome variables measured with the following
questionnaires (Table 2). PTSD symptoms are measured
using the PTSD Checklist for DSM-5 (PCL-5) [53], a 20-
item self-report questionnaire that assesses the presence of
the four core DSM-5 PTSD symptom clusters during the
past month. The Dissociative Symptoms Scale (DSS) [12] is
used to measure the presence of dissociative symptoms.
DSS is a 20-item self-report questionnaire measuring four
domains of dissociation: depersonalization, derealization,
gaps in awareness or memory, and dissociative re-
experiencing. The patient’s general level of psychological
distress is measured with the Symptom Checklist-10 (SCL-
10) [3], a 10-item measure of general psychological distress,
derived from the Symptom Checklist-90 (SCL-90). SCL-10
is composed of questions that measure the three factors of
the SCL-90 that accounts for the largest amount of vari-
ance: depression, somatization, and phobic anxiety. WHO-5
[2] is used to measure the patients’ quality of life. WHO-5
is a 5-item self-report questionnaire that measures well-
being during the last 2 weeks. Patient sleep quality is mea-
sured with the Sleep Condition Indicator (SCI) [25, 37], an
8-item questionnaire. The patient’s readiness to change is
measured with The University of Rhode Island Change As-
sessment Short version (URICA-S) [41], a short version of
the URICA self-report questionnaire [42]. URICA-S is a 16-
item measure. Possible negative effects of the PTSD help
intervention are measured with the Negative Events and Re-
sults of Psychological Treatment–Revised (NEQ-rev) [31,
49], a 13-item self-report questionnaire that aims to assess
negative effects associated with psychotherapeutic interven-
tions, e.g., suicidal thoughts, lower self-esteem, increased
stress level, and worsening of symptoms. NEQ-rev is a
revised version of NEQ. All items in NEQ that directly con-
cern treatment-related conditions or outcomes of psycho-
therapy are excluded (see Additional file 2 for a list of
excluded items), as the patients do not undergo psycho-
therapeutic treatment at the time NEQ-R is administered.
To measure user experiences, the user satisfaction question-
naire was developed by the project group. This is a 17-item
self-report questionnaire that assesses the patient’s per-
ceived benefit from using the app PTSD help. The project
group developed the questionnaire selecting, translating,
and modifying relevant items from two questionnaires used
for evaluation of the PTSD Coach app by Kuhn et al. [33]
and Miner et al. [44] (see Additional file 1).
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Adverse events
As the interventions included in the app does not in-
clude any trauma-focused interventions or other symp-
tom provoking interventions, we do not expect any
adverse effect from use of the app. However, to ascertain
whether this assumption is correct, we include the Nega-
tive Events and Results of Psychological Treatment–Re-
vised to measure possible adverse effects.
Statistical analysis
The primary and secondary outcomes are analyzed
through descriptive statistics, e.g., percentage of patients
that show up at T2, the average usage of the system over
the intervention period, and the proportion of patients
that stay in study until the end.
Analysis of between-group effects on explorative outcome
measures will be analyzed with analysis of covariance, using
the intervention arm as the main predictor and baseline se-
verity and the stratification variable from randomization as
covariates. For binary outcomes (e.g., compliance), logistic
regression will be used. Due to the exploratory nature of
this feasibility study, missing data will not be imputed but
the amount of missingness will be reported. Results will be
presented as covariate adjusted group differences or odds
ratios, along with the 95% confidence interval. If the results
indicate feasibility, we will proceed to a randomized con-
trolled efficacy study.
Sample size
Due to a shortage of similar studies, it is not currently
possible to conduct a calculation of optimal sample size
for this study. Based on existing knowledge about feasi-
bility study methodology [6, 52, 54] and two feasibility
studies of mHealth tool in public health settings [9, 26],
we plan to recruit 70 patients. With 70 patients, the 95%
confidence interval for a proportion estimate such as
compliance would range between 0.38 and 0.62 (if the
observed proportion is 0.50), which we consider accept-
able for planning further studies.
Discussion
The aim of this trial is to investigate the feasibility of
implementing a large scale RCT of the PTSD help app
and to generate hypotheses about the effectiveness of
PTSD help for psychiatric patients suffering from PTSD
in a Danish psychiatric setting. The results of this trial
will be used to inform a potential RCT by providing data
for sample size estimation, optimizing the recruitment
procedure with regards to the exclusion and inclusion
criteria, identifying roadblocks for patients use of the
app and supplying information about potential modifica-
tion to the content of the app, both through analysis of
the patients app use patterns, and responses on the user
behavior questionnaires. In addition, as this is, to our
knowledge, the first trial of a mHealth supplement for
Table 2 SPIRIT figure
T1 enrollment, baseline assesment, and randomization, T2 post-primary app intervention 6 weeks after baseline, T3 end of psychotherapy treatment, MINI Mini-
International Neuropsychiatric Interview, THQ Trauma History Questionnaire, I International Trauma Questionnaire, PCL-5 PTSD Checklist for DSM-5, SCI Sleep Condition
Indicator, DSS Dissociative Symptoms Scale,WHO-5 WHO-Five Well-being Index, SCL-10 Symptom Checklist-10, URICA-S University of Rhode Island Change Assessment
Scale-Short, NEQ Negative Effects Questionnaire, Feasibility and Acceptability Questionnaires developed specifically for this project by the research team
aRevised version of NEQ, 13 questions selected
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PTSD treatment is in a Danish population. This study
may help increase our knowledge of possible benefits of,
as well as potential barriers to, the implementation of
mHealth tools. In the future, this may assist the develop-
ment and implementation of mHealth tools for a range
of psychiatric disorders. This may have the potential to
increase therapy outcomes and decrease duration of
suffering and the costs of treatment in the Danish psy-
chiatric sector. In addition, this study can provide infor-
mation on the effect of providing interventions in the
pre-treatment period, as opposed to the waiting list con-
dition. The measurements of clinical variables in this
time period will also provide information on the effect
of the pretreatment period.
As the study is a feasibility study, it has several limita-
tions. First and foremost, due to the small sample size, it
will be impossible to test the clinical effect on the vari-
ous outcome measures. However, the relatively small
sample size is deemed adequate to determine feasibility,
which is the primary goal of the study. An additional
limitation is that the study setting has made it impos-
sible to create homogenous experimental and control
therapy groups in the group setting, in that there will be
a mix of patients from the two conditions in the therapy
groups. Another limitation due to the study setting is
that patient may receive a relatively wide variety of
pharmacological treatments at different time points dur-
ing the trial, information about which is not available to
the research group due to GDPR rules limiting access to
patient medical information. This lack of consistency in
pharmacological treatment across patients limits the pos-
sibility to assess the direct impact of the app intervention,
though this is partially mitigated by randomization. A gen-
eral limitation in studies including mHealth tools in a psy-
chiatric setting is that even though a large majority of
adults have access to a smartphone, some do not, which
will limit possible intake applicability of mHealth tools.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40814-020-00633-x.
Additional file 1. PTSD help user behaviour.
Additional file 2. Excluded NEQ items.
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